Retatrutide is an emerging multi-receptor agonist primarily used to treat obesity and metabolic diseases. It simultaneously activates three incretin receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This multi-mechanism gives retatrutide great potential for weight management, blood sugar control, and overall metabolic health.